Limits...
Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.

Nodin B, Zendehrokh N, Brändstedt J, Nilsson E, Manjer J, Brennan DJ, Jirström K - J Ovarian Res (2010)

Bottom Line: AR expression was not related to prognosis in the entire cohort, but in the serous subtype (n = 90), AR positivity (> 10% positive nuclei) was associated with a prolonged disease specific survival in univariate (HR= 0.49; 95% CI 0.25-0.96; p= 0.038) and multivariate (HR= 0.46; 95% CI 0.22-0.97; p= 0.042) analysis, adjusted for age, grade and clinical stage.AR expression is considerably reduced in EOC as compared to fallopian tubes, and in EOC of the serous subtype, high AR expression is a favourable prognostic factor.These results indicate that assessment of AR expression might be of value for treatment stratification of EOC patients with serous ovarian carcinoma.

View Article: PubMed Central - HTML - PubMed

Affiliation: Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, and Skåne Regional Laboratories, Malmö, Sweden. karin.jirstrom@med.lu.se.

ABSTRACT

Background: Altered androgen hormone homeostasis and androgen receptor (AR) activity have been implicated in ovarian carcinogenesis but the relationship between AR expression in ovarian cancer and clinical outcome remains unclear.

Methods: In this study, the prognostic impact of AR expression was investigated using immunohistochemistry in tissue microarrays from 154 incident cases of epithelial ovarian cancer (EOC) in the prospective, population-based cohorts Malmö Diet and Cancer Study and Malmö Preventive Project. A subset of corresponding fallopian tubes (n = 36) with no histopathological evidence of disease was also analysed.

Results: While abundantly expressed in the majority of fallopian tubes with more than 75% positive nuclei in 16/36 (44%) cases, AR was absent in 108/154 (70%) of EOC cases. AR expression was not related to prognosis in the entire cohort, but in the serous subtype (n = 90), AR positivity (> 10% positive nuclei) was associated with a prolonged disease specific survival in univariate (HR= 0.49; 95% CI 0.25-0.96; p= 0.038) and multivariate (HR= 0.46; 95% CI 0.22-0.97; p= 0.042) analysis, adjusted for age, grade and clinical stage.

Conclusions: AR expression is considerably reduced in EOC as compared to fallopian tubes, and in EOC of the serous subtype, high AR expression is a favourable prognostic factor. These results indicate that assessment of AR expression might be of value for treatment stratification of EOC patients with serous ovarian carcinoma.

No MeSH data available.


Related in: MedlinePlus

Impact of androgen receptor expression on ovarian cancer specific survival. Kaplan-Meier curves visualizing OCSS according to AR expression in all tumors (A) and serous carcinomas (B), using a threshold of 10% positive nuclei to define low and high AR expression. The total number of events was 52/71 (73%) in AR high serous tumors and 11/19 (58%) in AR low serous tumors.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2902477&req=5

Figure 2: Impact of androgen receptor expression on ovarian cancer specific survival. Kaplan-Meier curves visualizing OCSS according to AR expression in all tumors (A) and serous carcinomas (B), using a threshold of 10% positive nuclei to define low and high AR expression. The total number of events was 52/71 (73%) in AR high serous tumors and 11/19 (58%) in AR low serous tumors.

Mentions: Analysis of the entire cohort (n = 154) revealed no relationship between increased AR expression (> 10%) in primary tumors and outcome (Figure 2A). However, subset analysis in serous carcinomas (n = 90) revealed that increased AR expression was associated with a prolonged OCSS (p = 0.034) (Figure 2B). Cox univariate analysis confirmed the association between AR and OCSS in serous carcinomas (HR= 0.49; 95% CI 0.25-0.96; p= 0.038) and this association remained significant in a multivariate model controlling for age, grade and stage (HR= 0.46; 95% CI 0.22-0.97; p= 0.042). AR was not prognostic in non-serous carcinomas (data not shown).


Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.

Nodin B, Zendehrokh N, Brändstedt J, Nilsson E, Manjer J, Brennan DJ, Jirström K - J Ovarian Res (2010)

Impact of androgen receptor expression on ovarian cancer specific survival. Kaplan-Meier curves visualizing OCSS according to AR expression in all tumors (A) and serous carcinomas (B), using a threshold of 10% positive nuclei to define low and high AR expression. The total number of events was 52/71 (73%) in AR high serous tumors and 11/19 (58%) in AR low serous tumors.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2902477&req=5

Figure 2: Impact of androgen receptor expression on ovarian cancer specific survival. Kaplan-Meier curves visualizing OCSS according to AR expression in all tumors (A) and serous carcinomas (B), using a threshold of 10% positive nuclei to define low and high AR expression. The total number of events was 52/71 (73%) in AR high serous tumors and 11/19 (58%) in AR low serous tumors.
Mentions: Analysis of the entire cohort (n = 154) revealed no relationship between increased AR expression (> 10%) in primary tumors and outcome (Figure 2A). However, subset analysis in serous carcinomas (n = 90) revealed that increased AR expression was associated with a prolonged OCSS (p = 0.034) (Figure 2B). Cox univariate analysis confirmed the association between AR and OCSS in serous carcinomas (HR= 0.49; 95% CI 0.25-0.96; p= 0.038) and this association remained significant in a multivariate model controlling for age, grade and stage (HR= 0.46; 95% CI 0.22-0.97; p= 0.042). AR was not prognostic in non-serous carcinomas (data not shown).

Bottom Line: AR expression was not related to prognosis in the entire cohort, but in the serous subtype (n = 90), AR positivity (> 10% positive nuclei) was associated with a prolonged disease specific survival in univariate (HR= 0.49; 95% CI 0.25-0.96; p= 0.038) and multivariate (HR= 0.46; 95% CI 0.22-0.97; p= 0.042) analysis, adjusted for age, grade and clinical stage.AR expression is considerably reduced in EOC as compared to fallopian tubes, and in EOC of the serous subtype, high AR expression is a favourable prognostic factor.These results indicate that assessment of AR expression might be of value for treatment stratification of EOC patients with serous ovarian carcinoma.

View Article: PubMed Central - HTML - PubMed

Affiliation: Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, and Skåne Regional Laboratories, Malmö, Sweden. karin.jirstrom@med.lu.se.

ABSTRACT

Background: Altered androgen hormone homeostasis and androgen receptor (AR) activity have been implicated in ovarian carcinogenesis but the relationship between AR expression in ovarian cancer and clinical outcome remains unclear.

Methods: In this study, the prognostic impact of AR expression was investigated using immunohistochemistry in tissue microarrays from 154 incident cases of epithelial ovarian cancer (EOC) in the prospective, population-based cohorts Malmö Diet and Cancer Study and Malmö Preventive Project. A subset of corresponding fallopian tubes (n = 36) with no histopathological evidence of disease was also analysed.

Results: While abundantly expressed in the majority of fallopian tubes with more than 75% positive nuclei in 16/36 (44%) cases, AR was absent in 108/154 (70%) of EOC cases. AR expression was not related to prognosis in the entire cohort, but in the serous subtype (n = 90), AR positivity (> 10% positive nuclei) was associated with a prolonged disease specific survival in univariate (HR= 0.49; 95% CI 0.25-0.96; p= 0.038) and multivariate (HR= 0.46; 95% CI 0.22-0.97; p= 0.042) analysis, adjusted for age, grade and clinical stage.

Conclusions: AR expression is considerably reduced in EOC as compared to fallopian tubes, and in EOC of the serous subtype, high AR expression is a favourable prognostic factor. These results indicate that assessment of AR expression might be of value for treatment stratification of EOC patients with serous ovarian carcinoma.

No MeSH data available.


Related in: MedlinePlus